Mutations in either IDH1 or IDH2, commonly seen in glioblastomas, contribute to downregulation of BCAT1 through DNA methylation of the BCAT1 promoter and the corresponding epigenetic silencing of BCAT1[10] (Table 1). This evidence concerns the gene IDH1 and glioblastoma.